Early Degeneration of Both Dopaminergic and Serotonergic Axons – A Common Mechanism in Parkinson’s Disease

Janina Grosch, Jürgen Winkler and Zacharias Kohl*

Department of Molecular Neurology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany

Motor symptoms in Parkinson’s disease (PD) are tightly linked to the degeneration of substantia nigra dopaminergic neurons and their projections into the striatum. Moreover, a broad range of non-motor symptoms like anxiety and depression frequently occur in PD, most likely related to the loss of serotonergic neurons and their projections into corresponding target regions. Strikingly, nigral dopaminergic neurons and raphe serotonergic neurons are severely affected in PD showing characteristic hallmarks of PD neuropathology, in particular alpha-synuclein containing Lewy bodies and Lewy neurites. So far, the initial events underlying neurodegenerative processes in PD are not well understood. Several observations, however, indicate that neurites and synapses of diseased neurons may be the first subcellular compartments compromised by alpha-synuclein associated pathology. In particular axonal pathology and deficits in axonal transport may be leading to the onset of synucleinopathies such as PD. This review will highlight current findings derived from imaging and neuropathological studies in PD patients, as well as cellular and animal PD models, which define the initial underlying structural and molecular events within dopaminergic and serotonergic circuits leading to the ‘dying back’ degeneration of axonal projections in PD.

Keywords: Parkinson’s disease, axon degeneration, dying back, synaptic loss, dopamine, 5-HT

INTRODUCTION

Parkinson’s disease (PD) represents the second most common neurodegenerative disorder, affecting up to ten million people worldwide (de Lau and Breteler, 2006), with a predicted increase of more than twofold by 2030 (Dorsey et al., 2007). PD patients show progressive motor symptoms such as bradykinesia, rigidity, and resting tremor. Moreover, PD is accompanied by a broad range of non-motor symptoms (NMS), including cognitive deficits, autonomic dysfunctions, and mood disorders (Marras and Chaudhuri, 2016). While the etiology of PD still remains unclear, the aggregation of the presynaptic protein alpha-synuclein, either within Lewy bodies or Lewy neurites of susceptible neurons is of ultimate diagnostic value (Dickson et al., 2009). The other major neuropathological hallmark of PD is the degeneration and subsequent loss of dopaminergic neurons in the substantia nigra (SN) leading to prototypic motor deficits (Greffard et al., 2006). Interestingly, Lewy pathology was also described in numerous other neuronal subpopulations in distinct brain regions, most likely occurring even prior to dopaminergic SN neurons, e.g., in the medulla oblongata, olfactory bulb, and pontine tegmentum (Braak et al., 2003). These findings are paralleled by deficits of several neurotransmitter systems including serotonergic, noradrenergic,
cholinergic, GABAergic, and glutamatergic signaling (reviewed in Brichta et al., 2013). PD pathology in these non-dopaminergic systems, in particular serotonergic neurotransmission, may be related to NMS like anhedonia, anxiety and depression, affecting up to 50% of PD patients and having a strong impact on patients’ quality of life (Gallagher and Schrag, 2012; Duncan et al., 2014; Bugalho et al., 2016).

Several studies imply that dysfunction of different neurotransmitter systems occur even prior to the presence of Lewy pathology and the consequent neuronal loss [e.g., reviewed in (Burke and O’Malley, 2013)]. This led to the overall hypothesis, that the main pathophysiological process is related to a “dying back” of axons prior to the loss of neuronal perikarya (Hornykiewicz, 1998; Cheng et al., 2010). This review will discuss recent findings of clinical and neuropathological studies, as well as molecular mechanisms from cellular and animal models supporting the concept of an early axonal pathology in PD.

LOSS OF DOPAMINERGIC NEURONS AND THEIR PROJECTIONS IN PD

The involvement of the nigrostriatal dopaminergic system in PD was noted as early as neuropsychological studies detected the loss of melanin-containing dopaminergic neurons in the SN of affected patients (Pakkenberg and Brody, 1965; Hirsch et al., 1988). The extent of neuronal loss in the SN by the time of clinical diagnosis was subject of several subsequent studies: While many reviews repeatedly state that first motor symptoms appear after 50% of SN dopaminergic neurons are lost (Lang and Lozano, 1998; Chandhagopal et al., 2008), comprehensive clinico-neuropathological studies used regression analysis to more precisely determine the loss of dopaminergic neurons at the time of symptom onset. Fearnley and Lees (1991) estimated the percentage of lost pigmented SN neurons at symptom onset by 31%. Subsequent stereological analyses provided similar results extrapolating the number of remaining pigmented SN neurons to the time of motor symptom onset to about 70% (Ma et al., 1997; Greffard et al., 2006). In summary, neuropathological-clinical correlations suggest that initial motor signs in PD occur as early as around 30% of total SN neurons are lost.

In contrast, the loss of dopaminergic striatal nerve terminals at motor symptoms onset is rather difficult to determine: An early neurochemical study focused on caudate dopamine levels in post-mortem tissue in two different cohorts (about 60 years vs. 73 years of age), and allowed an extrapolation to the time of symptom onset ranging from 68 to 82% of dopamine reduction (Riederer and Wuketich, 1976). To circumvent the concerns about post-onset ranging from 68 to 82% of dopamine reduction (Riederer et al., 1989), Here, the regression analysis indicated a loss of 49% of binding sites by the time of motor symptom onset. In general, the loss of dopamine terminals is higher in the putamen compared to the caudate (Kish et al., 1988), allowing the assumption that the loss of binding in the putamen ranges even higher than 50% by the time of onset of motor symptoms. Recently, Kordower et al. (2013) described in detail the integrity of nigrostriatal dopaminergic connectivity using tyrosine hydroxylase (TH) and dopamine transporter (DAT) as markers for dopaminergic function: In PD, dopaminergic fiber density in the dorsal putamen was rapidly and severely decreased leading to a virtually complete neuritic loss at 4 years after the clinical diagnosis compared to controls. In contrast, TH+ SN neurons were less severely affected from the earliest time points on, with a minor loss over time, resulting in a residual population of dopaminergic neurons even decades after diagnosis (Kordower et al., 2013). In another study, this group detected an early loss of kinesin protein (anterograde transport motor protein) in the putamen of PD patients (H&Y stage 1 and 2), representing axonal loss, while reductions of typical cytoplasmic proteins like dynein light chain Tctex 3 as well as TH protein levels in the SN were only observed at later PD stages (Chu et al., 2012). Taken together, these observations support the hypothesis of an early axonal degeneration involving transport deficits in PD.

IMPAIRED NIGROSTRIATAL DOPAMINERGIC PROJECTIONS IN VIVO

While there are concerns about the significance of neuro-pathological and -chemical measures due to post-mortem delay, several in vivo studies investigated axonal or synaptic loss by using radioligand imaging (reviewed recently by Politis, 2014), in particular measuring DAT and VMAT2 (Table 1). Again, particularly those studies performing regression analysis to the onset of motor symptoms are relevant: the proportion of lost striatal and putaminal dopaminergic terminals was estimated up to 56% (Schwartz et al., 2004). Using [123I]beta-CIT SPECT to label presynaptic DAT an early study described a loss of dopaminergic terminals contralateral to the unaffected side by 39–51% in the striatum and 51–64% in the putamen (Tissingh et al., 1998). In a larger study using two different PET markers, for DAT and VMAT2, the loss of putaminal dopaminergic innervation was between 51 and 71% for both tracers (Lee et al., 2000). More recent work using these established PET markers suggests that younger PD patients are able to compensate over several years the progressive dysfunction of the dopaminergic system before the first motor symptoms are recognized (de la Fuente-Fernandez et al., 2011).

At present, neuro-pathological and -imaging findings suggest that at the onset of motor symptoms in PD the loss of striatal or putaminal dopaminergic projections largely exceeds that of dopaminergic SN neurons, again supporting the hypothesis of a “dying back” of axons to their dopaminergic perikarya in PD (Cheng et al., 2010; Chu et al., 2012; Burke and O’Malley, 2013).

LOSS OF SEROTONERGIC NEURONS AND THEIR PROJECTIONS IN PD

Serotonergic neurotransmission is widely distributed in the brain and mediated by serotonergic neurons in...
TABLE 1 | Parkinson’s disease (PD) imaging studies of dopaminergic and serotonergic deficits.

| Modality | Method | Ligand | N  | Region | Marker loss (%) | Type of analysis | Reference |
|----------|--------|--------|----|--------|----------------|-----------------|-----------|
| Dopamine imaging | DAT binding | SPECT [123I]-IPT | 6 | Striatum | 43 | Regression to time of symptom onset | Schwartz et al., 2004 |
| | SPECT [123I]-β-CIT | 8 (H&Y I) | Striatum | 39–51 | H&Y I (ipsi- vs. contralateral) | Tissingh et al., 1998 |
| | Putamen | 56 | | | | | |
| | PET [11C]-MP | 13 (H&Y I) | Putamen | 56–71 | H&Y I (ipsi- vs. contralateral) | Lee et al., 2000 |
| | PET [11C]-DTBZ | 13 (H&Y I) | Putamen | 51–62 | H&Y I (ipsi- vs. contralateral) | Lee et al., 2000 |
| | PET [11C]-DTBZ | 78 (H&Y I-II) | Putamen | 71 (younger) | Regression to time of symptom onset; younger vs. older age of onset | de la Fuente-Fernandez et al., 2011 |
| | | | | 34 (older) | | | |
| Serotonin imaging | SERT binding | PET [11C]McN5652 | 13 | Caudate | 50 | H&Y I-IV vs. controls | Kerenyi et al., 2003 |
| | PET [11C]-DASB | 9 | Caudate | 30 | H&Y II-III vs. controls | Guttman et al., 2007 |
| | | | Putamen | 26 | | | |
| | | | Midbrain | 29 | | | |
| | | | Orbitofrontal cortex | 22 | | | |
| | PET [11C]-DASB | 5 | Forebrain regions | 40–50 | H&Y I-II,5 vs. controls | Albin et al., 2008 |
| | | | Caudal brain stem regions | ~20 | | | |
| | PET [11C]-DASB | 30 | Caudate | 28 | H&Y I-II vs. controls | Politis et al., 2010 |
| | | | Thalamus | 17 | | | |
| | | | Anterior cingulate cortex | 32 | | | |
| | | | + Putamen | 33 | H&Y II-III vs. controls | | |
| | | | + Prefrontal cortex | 40 | | | |
| | | | + Raphe nuclei | 19/22 | H&Y III-IV vs. controls | | |
| | | | + Amygdala | 25 | | | |
| | PET [11C]-DASB | 30 | Ventral striatum | | Significant loss | Apathetic vs. non-apathetic drug naïve early PD | Maillet et al., 2016 |
| | | | Anterior cingulate cortex | | | | |
| | | | Caudate (R) | | | | |
| | | | Orbitofrontal cortex (R) | | | | |

IPT, N-(3-iodopropen-2-yl)-2beta-carboxymethoxy-3beta-[4-chlorophenyl]-tropane; β-CIT, beta-carbomethoxy-3 beta-[4-iodophenyl]tropane; MP, methylphenidate; DTBZ, dihydrotetrabenazine; McN5652, [2,3,5,6,10j(thexahydro6f4(methylthio)phenyl)pyrrolo[2,1-a]isoquinoline]; DASB, 3-amino-4-[2-dimethylaminomethylphenylsulfonyl]-benzonitrile.

the raphe nuclei (RN). Clusters of rostral RN neurons mainly project to the forebrain innervating basal ganglia, amygdala, hippocampus, hypothalamus, and several cortical regions (Parent et al., 2011; Wallman et al., 2011). Important functions are linked to the serotonergic system including motor function, as well as cognition and mood: Dysfunction of serotonin (5-hydroxytryptamine, 5-HT) neurotransmission contributes to resting tremor and levodopa-induced dyskinesias (Doder et al., 2003; Rylander et al., 2010; Politis et al., 2014) as well as to typical NMS of PD, in particular apathy, anxiety, anhedonia, and depression (Pavese et al., 2010; Ballanger et al., 2012).

Neuropathological analyses demonstrated an early involvement of serotonergic neurons in PD (Halliday et al., 1990; Paulus and Jellinger, 1991), associated with the presence of Lewy pathology within the RN at an early disease stage (Braak et al., 2003; Seidel et al., 2015). In detail, work by Halliday et al. (1990) described a loss of serotonergic neurons in the median RN of PD patients by 56%. Intriguingly, serotonergic cell loss was correlated with depression in PD, revealing an increased cell loss in the RN of depressed PD patients (Paulus and Jellinger, 1991). Typical NMS, possibly related to the serotonergic system like anxiety or depression, are often present before the onset of motor symptoms (Weintraub et al., 2015). Moreover, serotonin depletion was observed in several target regions of the RN including basal ganglia, hypothalamus, hippocampus, and prefrontal cortex (Fahn et al., 1971; Shannak et al., 1994). In addition, levels of serotonin transporter (SERT) immunoreactivity, protein levels of tryptophan hydroxylase, 5-HT and its metabolites were reduced in the caudate nucleus compared to the putamen in post-mortem tissue from PD patients (Kish et al., 2008).
IN VIVO STUDIES ADDRESSING THE SEROTONERGIC SYSTEM IN PD

Specific radioligands for the serotonergic system allowed new insights in PD related alterations in vivo (Table 1): Besides selective radiotracers for 5-HT receptors, particularly the highly selective detection of SERT using $[^{11}C]$-DASB PET enabled tracing of serotonergic terminals in the brain. Early studies detected a reduced SERT binding in the caudate nucleus and the putamen of PD patients (Kerenyi et al., 2003; Guttmann et al., 2007). A follow-up study stratified for disease duration and without history of depression, described in detail an early loss of serotonergic terminals in the caudate nucleus, thalamus, hypothalamus, and anterior cingulum, followed by further deficits in putamen, insula, posterior cingulum, and prefrontal cortex in PD (Politis et al., 2010). Interestingly, the loss of SERT binding in the caudal and rostral RN occurred in advanced disease stages only, which points to an earlier affection of serotonergic projections compared to serotonergic neurons. This notion was supported by another $[^{11}C]$-DASB-PET study showing reduced forebrain, but preserved brain stem SERT binding in PD patients (Albin et al., 2008). Interestingly, a recent PET study in PD patients without signs of apathy mainly showed dopaminergic denervation, while serotonergic innervation remained preserved. In contrast, PD patients with apathy exhibited additional dopaminergic loss within the right caudate, insula, orbitofrontal cortex, and cingulum without prominent dopaminergic deficits (Mailet et al., 2016). Despite these new insights into the dysfunction of the serotonergic system in PD, a temporal dissociation of the loss of serotonergic terminals in the forebrain and the number of RN neurons has not been well established, although these imaging studies point to an early degeneration of serotonergic nerve terminals.

AXONAL DEGENERATION IN MURINE PD MODELS

In order to get a more precise insight into the temporal pattern of degenerative events, several animal as well as cellular models are relevant:

Numerous transgenic animal models for PD have been generated, mostly carrying mutations in genes associated with monogenic PD such as alpha-synuclein, leucine rich repeat kinase 2 (LRRK2), Parkin, PTEN-induced putative kinase 1 (PINK1), and protein deglycase DJ-1 (reviewed by Lee et al., 2012). Longitudinal studies provide important information about the temporal progression of neurodegenerative events within the dopaminergic system (Figure 1).

Chung et al. (2009) injected adeno-associated virus (AAV) 2 encoding for human A53T alpha-synuclein into the SN of rats. After 4 weeks, dopaminergic axons within the striatum were dystrophic and swollen, and levels of dynein, mediating retrograde axonal transport, were significantly decreased. Eight weeks after AAV injection, several microtubule based motor proteins required for anterograde transport were reduced in the striatum. Since these findings were not observed in the SN, an initial impairment of dopaminergic axons is implied. BAC alpha-synuclein transgenic mice, expressing human alpha-synuclein had a reduced striatal dopamine release without a loss of dopaminergic SN neurons at 3 months of age (Janezic et al., 2013). In contrast, the number of dopaminergic SN neurons was significantly reduced in aged (18-month-old) mice accompanied by a motor phenotype. This temporal pattern of structural and functional measures indicated an early axonal phenotype prior to the loss of SN perikarya. Using another BAC alpha-synuclein construct, an increased DAT level in whole brain lysates without reduction of dopaminergic SN neurons was observed in 24-month-old mice (Yamakado et al., 2012). BAC transgenic rats overexpressing full-length human alpha-synuclein show a severe motor impairment at 12 months of age with severe striatal dopamine depletion. Importantly, TH+ striatal fibers and TH+ SN neurons were reduced in 18-month-old rat, but not in 3-month-old rat (Nuber et al., 2013).

While there was already some evidence for the onset of PD pathology within projection areas of dopaminergic neurons, recent animal studies revealed a similar temporal pattern of events within the serotonergic system of murine PD models (Figure 1).

Aforementioned BAC transgenic rats (published by Nuber et al., 2013) additionally display severe impairment of hippocampal neurogenesis, a feature strongly associated with early behavioral phenotypes like depression and anxiety at 4 months of age, even prior to the onset of a motor phenotype (Kohl et al., 2016). Impaired hippocampal neurogenesis was accompanied by a profoundly reduced serotonergic innervation of the hippocampal dentate gyrus (DG; Kohl et al., 2016). Furthermore, 5-HT receptor expression was altered and 5-HT levels were significantly reduced in the hippocampal DG and CA3 region of transgenic animals, strongly indicating an early dysfunction of serotonergic terminals. The number of serotonergic neurons in the RN, however, remained unaltered. This temporal pattern of structural changes and the functional phenotype in the BAC transgenic rat model demonstrates that an early axonal phenotype preceding the loss of perikarya is also present in the serotonergic system in PD. Further evidence for an early axonal phenotype within the serotonergic system derives from the A53T alpha-synuclein mouse model (A53T mice) of PD. At 52 weeks of age, human synuclein was expressed in serotonergic RN neurons and their projections within the hippocampal formation (Deussler et al., 2015). While the number of serotonergic neurons was preserved in A53T mice, the density of serotonergic fibers within the dorsal DG was severely reduced. Furthermore, viral injections allowing the overexpression of alpha-synuclein selectively in serotonergic neurons resulted in a progressive degeneration of serotonergic axon terminals in the hippocampus, while the number of serotonergic RN neurons remained unaltered (Wan et al., 2016). Mutations in PINK1 are linked to monogenic forms of PD, as well. PINK1 deficient mice showed no motor phenotypes, but olfactory deficits at 19 months of age (Glasl et al., 2012). Olfactory dysfunction is a very common NMS in PD. Interestingly, serotonergic innervation was significantly diminished in the glomerular layer of the olfactory bulb, while again there was no reduction in the...
FIGURE 1 | (A) Loss of dopaminergic terminals (stained for tyrosine hydroxylase, TH) in the striatum precedes loss of substantia nigra pars compacta (SNpc) dopaminergic neurons in transgenic mouse models of PD. (B) While the number of serotonergic neurons within the medium raphe nuclei (mRN) was not changed in different transgenic mouse models of PD, the innervation of the hippocampal formation (stained for serotonin transporter, SERT) and the glomerular layer of the olfactory bulb was diminished together with depressive symptoms and impaired olfaction, respectively.

numbers of serotonergic RN neurons. This study also strongly indicates an early loss of serotonergic terminals in a second target region besides the hippocampal formation associated with NMS in PD.

Besides transgenic PD models acute neurotoxic models using toxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 6-hydroxydopamine (6-OHDA) specifically target dopaminergic SN neurons (reviewed by Blandini and Armentero, 2012). 6-OHDA is commonly injected directly into the striatum or the medial forebrain bundle, thereby directly damaging dopaminergic terminals. Few studies applied unilateral intranigral injections and revealed a severe loss of TH⁺ neurons associated with a severe reduction of dopaminergic fibers (Moses et al., 2008; Grealish et al., 2010). For systemic application of MPTP which specifically diminishes dopaminergic neurons a severe loss of TH⁺ striatal fibers was observed, but the temporal pattern of these events was not analyzed in detail. One day after MPTP treatment Serra et al. detected a 60% reduction of striatal dopaminergic fibers without significant increase in apoptotic TUNEL positive cells within the SN (Serra et al., 2002).

NEURITE DEGENERATION IN HUMAN STEM CELL MODELS OF PD

The opportunity to model PD by reprogramming patient derived cells into induced pluripotent stem cells (iPSC) and differentiating them into neurons recently advanced the availability of human cellular models of PD. Human dopaminergic neurons of sporadic and LRRK2 PD patients (carrying the G2019S mutation) showed markedly less neurites per dopaminergic neuron and shorter neurites in both patient cohorts after 75 days of neuronal differentiation. The number of caspase3 positive cells, however, was also significantly increased in patient derived neurons pointing toward higher rates of cell death in these cultures. The neuritic phenotype appeared rather simultaneously to the degeneration of the dopaminergic neurons in this iPSC derived PD model. Using another approach to generate dopaminergic neurons from LRRK2 patient derived iPSC carrying the identical G2019S mutation, Borgs et al. (2016) detected a different phenotype. LRRK2 patient derived neurons that were generated from neural progenitor cells using small molecules showed a reduced total neurite length and increased neurite branching while the number of TH positive neurons was not altered after 35 days of differentiation.

CONCLUDING REMARKS/ PERSPECTIVES

Enormous progress in imaging techniques, a large variety of animal models and the availability of PD patient iPSC derived
neurons helped to significantly improve our knowledge of the temporal pattern of pathomechanisms underlying PD. Given the early appearance of NMS in PD and their tremendous impact on the patients’ quality of life it is important to compare the timeline of pathogenic events within the serotonin system with those more soundly explored in the dopaminergic system. One important recent milestone in PD research represents the appreciation that the onset of the disease may take place at the synaptic site and within the axonal compartment. Another milestone in PD research is the focus on other neurotransmitter systems besides dopamine, since especially early phenotypes of PD are strongly associated with e.g., alterations of the serotoninergic system. One possible mechanism underlying axonal degeneration in PD may be the impairment of axonal transport due to protein aggregation, cytoskeleton instability, or motor protein dysregulation (Lee et al., 2006; Esteves et al., 2010; Volpicelli-Daley et al., 2014). Whether protein aggregation within the axon, motor protein dysfunction, or disturbance of motor protein binding to microtubules initiates the impairment of axonal transport remains to be elucidated. Another initial mechanism may be the reorganization of the synapse including altered availability of neurotransmitter receptors and transporters. Focusing on the mechanisms of axonal degeneration both in the dopaminergic and the serotoninergic system or potentially even inducing axonal regeneration may be a very promising strategy to intervene at a very early stage with disease progression.

FUNDING
This work is supported by the Bavarian State Ministry of Education, Science, and the Arts (ForIPS grant).

AUTHOR CONTRIBUTIONS
JG, JW and ZK wrote the manuscript and designed figures/tables.

de Lau, L. M., and Breitel, M. M. (2006). Epidemiology of Parkinson's disease. Lancet Neurol. 5, 525–535. doi: 10.1016/S1474-4422(06)70471-9
Deußner, J., Schmidt, S., Ette, B., Plotz, S., Huber, S., Muller, C. P., et al. (2015). Serotonergic dysfunction in the AS3T alpha-synuclein mouse model of Parkinson's disease. J. Neurochem. 135, 589–597. doi: 10.1111/jn.13253
Dickson, D. W., Fujishiro, H., Orr, C., DelleDonne, A., Josephs, K. A., Frigerio, R., et al. (2009). Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat. Disord. 15(Suppl. 3), S1–S5. doi: 10.1016/S1353-8020(09)70769-2
Doder, M., Rabiner, E. A., Turjanski, N., Lees, A. J., Brooks, D. J., and 11C-Way 100635 Pet study, (2003). Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 60, 601–605. doi: 10.1212/01.WNL.000031424.51127.2B
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., et al. (2007). Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68, 384–386. doi: 10.1223/wnl.00000000000021955
Duncan, G. W., Khoo, T. K., Yarnall, A. J., O'Brien, J. T., Coleman, S. Y., Brooks, D. J., et al. (2014). Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov. Disord. 29, 195–202. doi: 10.1002/mds.26664
Esteves, A. R., Arduini, D. M., Swerdlow, R. H., Oliveira, C. R., and Cardoso, S. M. (2010). Microtubule depolymerization potentiates alpha-synuclein oligomerization. Front. Aging Neurosci. 2, 15. doi: 10.3389/fneuro.24.0005.2009
Fahn, S., Libsch, L. R., and Cutler, R. W. (1971). Monoamines in the human neonuatrum: topographical distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J. Neurol. Sci. 14, 427–455. doi: 10.1016/0022-510X(71)900178-X
Fearnley, J. M., and Lees, A. J. (1991). Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114(Pt 5), 2283–2301. doi: 10.1093/brain/114.5.2283
Gallagher, D. A., and Schrag, A. (2012). Psychosis, apathy, depression and anxiety in Parkinson’s disease. Neurobiol. Dis. 46, 581–589. doi: 10.1016/j.nbd.2011.12.041
Gläs, L., Klos, K., Giesert, F., Roethig, A., Di Benedetto, B., Kühn, R., et al. (2012). Pink1-deficiency in mice impairs gait, olfaction and serotonergic innervation of the olfactory bulb. Exp. Neurol. 235, 214–227. doi: 10.1016/j.expneurol.2012.01.002
Greali, S., Mattsson, B., Draxler, P., and Bjorklund, A. (2010). Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson’s disease. Eur. J. Neurosci. 31, 2266–2278. doi: 10.1111/j.1460-9586.2010.07265.x

REFERENCES
Albin, R. L., Koepppe, R. A., Bohnen, N. I., Wernette, K., Kilbourn, M. A., and Frey, K. A. (2008). Spared caudal brainstem SERT binding in early Parkinson's disease. J. Cereb. Blood Flow Metab. 28, 441–444. doi: 10.1038/jcbfm.9600599
Ballanger, B., Poisson, A., Broussolle, E., and Thobois, S. (2012). Functional imaging of non-motor signs in Parkinson's disease. J. Neurol. Sci. 315, 9–14. doi: 10.1016/j.jns.2011.11.008
Blandini, F., and Armengero, M. T. (2012). Animal models of Parkinson's disease. FEBS J. 279, 1156–1166. doi: 10.1111/j.1742-4658.2012.08491.x
Borgs, L., Peyre, E., Alix, P., Hanon, K., Grobczynk, B., Godin, J. D., et al. (2016). Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects. Sci. Rep. 6, 33377. doi: 10.1038/srep33377
Braak, H., Del Tredici, K., Rub, U., de Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 24, 197–211. doi: 10.1016/S0197-4580(02)00065-9
Britha, L., Greenberg, P., and Fajolet, M. (2013). Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems. Trends Neurosci. 36, 543–554. doi: 10.1016/j.tins.2013.06.003
Bugalho, P., Lampreia, T., Miguel, R., Mendonca, M. D., Caetano, A., and Barbosa, R. (2016). Non-Motor symptoms in Portuguese Parkinson's Disease patients: correlation and impact on quality of life and activities of daily living. Sci. Rep. 6, 32267. doi: 10.1038/srep32267
Burke, R. E., and O'Malley, K. (2013). Axon degeneration in Parkinson's disease. Exp. Neurol. 246, 72–83. doi: 10.1016/j.expneurol.2012.01.011
Cheng, H. C., Ulane, C. M., and Burke, R. E. (2010). Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 67, 715–725. doi: 10.1002/ana.21995
Chu, Y., Morfini, G. A., Langhamer, L. B., He, Y., Brady, S. T., and Kordower, J. H. (2012). Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 135, 2058–2073. doi: 10.1093/brain/aws133
Chung, C. Y., Koprich, J. B., Siddiqi, H., and Isacson, O. (2009). Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation preclude dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci. 29, 3365–3373. doi: 10.1523/JNEUROSCI.5427-08.2009
de la Fuente-Fernandez, R., Schulzer, M., Kuramoto, L., Ramachandiran, N., Au, W. L., Mak, E., et al. (2011). Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann. Neurol. 69, 803–810. doi: 10.1002/ana.22284
Greffard, S., Verny, M., Bonnet, A. M., Beinis, J. Y., Gallinari, C., Meaume, S., et al. (2006). Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch. Neurol. 63, 584–588. doi: 10.1001/archneur.63.4.584

Guttmann, M., Boileau, L., Ward, J., Saint-Cyr, J. A., Ginovart, N., McCluskey, T., et al. (2007). Brain serotonin transporter binding in non-depressed patients with Parkinson’s disease. Eur. J. Neurol. 14, 523–528. doi: 10.1111/j.1468-1331.2007.01727.x

Halliday, G. M., Blumbergs, P. C., Cotton, R. G., Blessing, W. W., and Geffen, L. B. (1990). Loss of brainstem serotonin- and substance P-containing neurons in Parkinson’s disease. Brain Res. 510, 104–107. doi: 10.1016/0006-8993(90)90733-R

Hirsch, E., Graybiel, A. M., and Agid, Y. (1988). Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 334, 345–348. doi: 10.1038/334345a0

Hornykiewicz, O. (1998). Biochemical aspects of Parkinson’s disease. Neurology 51, S2–S9. doi: 10.1212/wnl.51.2_Suppl_2.S2

Janezic, S., Threlfell, S., Dodson, P. D., Dowie, M. J., Taylor, N. T., Potgieter, D., et al. (2013). Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc. Natl. Acad. Sci. U.S.A. 110, E4016–E4025. doi: 10.1073/pnas.1309143110

Kerenyi, L., Ricautre, G. A., Schretlen, D. J., McCann, U., Varga, J., Mathews, W. B., Janezic, S., Threlfell, S., Dodson, P. D., Dowie, M. J., Taylor, T. N., Potgieter, D., Kohl, Z., Ben Abdallah, N., Vogelgsang, J., Tischer, L., Deusser, J., Amato, D., Marras, C., and Chaudhuri, K. R. (2016). Nonmotor features of Parkinson’s disease. Mov. Disord. 31, 345–348. doi: 10.1002/mds.26510

Moses, D., Drago, J., Teper, Y., Gantois, I., Finkielstein, D. I., and Horne, M. K. (2008). Fetal striatum- and ventral mesencephalon-derived expanded neurospheres rescue dopaminergic neurons in vitro and the nigro-striatal system in vivo. Neuroscience 154, 606–620. doi: 10.1016/j.neuroscience.2008.03.058

Politis, M., Wu, K., Loane, C., Brooks, D. J., and Beiser, A., et al. (2014). Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat. Rev. Neuro. 10, 708–722. doi: 10.1038/nrneurol.2014.205

Rydlander, D., Parent, M., O’Sullivan, S. S., Doversi, C., Lees, A. J., Bezard, E., et al. (2010). Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesias. Ann. Neurol. 68, 619–628. doi: 10.1002/ana.22097

Seidel, K., Mahlke, I., Siswanto, S., Krüger, R., Heinzen, I., and Aebischer, G. et al. (2015). The brainstem pathologies of Parkinson’s disease and dementia with Lewy bodies. Brain Pathol. 25, 121–135. doi: 10.1111/bpa.12168

Serra, P. A., Sciola, L., Delogu, M. R., Spano, A., Monaco, G., Miele, E., et al. (2007). In vivo positron emission tomographic evidence for compensatory changes in synapptic dopaminergic nerve terminals in Parkinson’s disease. Ann. Neurol. 61, 493–503. doi: 10.1002/ana.20934

Scherman, D., Desnos, C., Darchen, F., Pollak, P., Javoy-Agid, F., and Agid, Y. (1989). Striatal dopamine deficiency in Parkinson’s disease: role of aging. Ann. Neurol. 26, 551–557. doi: 10.1002/ana.410260409

Schwarz, M., Groshar, D., Inzelberg, R., and Hoehn-Sachs, H. (2004). Dopamine-transporter imaging and visuo-motor testing in essential tremor: practical possibilities for detection of early stage Parkinson’s disease. Parkinsonism Relat. Disord. 10, 385–389. doi: 10.1016/j.parkreldis.2004.03.004

Shannak, K., Rajput, A., Rozdilsky, B., Kish, S., Gilbert, J., and Hornykiewicz, O. (1994). Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson’s disease and normal subjects. Brain Res. 639, 33–41. doi: 10.1016/0006-8993(94)91761-2

Tissington, G., Boos, J., Bergmans, P., C. V., A. J., et al. (1998). Iodine-123-N-{alpha}-fluoropropyl-2beta-carboxyemodioic acid. J. Nucl. Med. 39, 1134–1148.

Volpicelli-Daley, L. A., Gamble, K. L., Schultheiss, C. E., Riddle, D. M., West, A. B., and Lee, V. M. (2014). Formation of alpha-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes. Mol. Biol. Cell 25, 4010–4023. doi: 10.1091/mbc.E14-02-0741
Grosch et al. Axonal Degeneration in PD

Wallman, M. J., Gagnon, D., and Parent, M. (2011). Serotonin innervation of human basal ganglia. *Eur. J. Neurosci.* 33, 1519–1532. doi: 10.1111/j.1460-9568.2011.07621.x

Wan, O. W., Shin, E., Mattsson, B., Caudal, D., Svenningsson, P., and Bjorklund, A. (2016). alpha-Synuclein induced toxicity in brain stem serotonin neurons mediated by an AAV vector driven by the tryptophan hydroxylase promoter. *Sci. Rep.* 6, 26285. doi: 10.1038/srep26285

Weintraub, D., Simuni, T., Caspell-Garcia, C., Coffey, C., Lasch, S., Siderowf, A., et al. (2015). Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson’s disease. *Mov. Disord.* 30, 919–927. doi: 10.1002/mds.26170

Yamakado, H., Moriwaki, Y., Yamasaki, N., Miyakawa, T., Kurisu, J., Uemura, K., et al. (2012). alpha-Synuclein BAC transgenic mice as a model for Parkinson’s disease manifested decreased anxiety-like behavior and hyperlocomotion. *Neurosci. Res.* 73, 173–177. doi: 10.1016/j.neures.2012.03.010

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Grosch, Winkler and Kohl. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.